Global enrollment is complete in the first of two pivotal trials that will back 2018 regulatory filings for the experimental oral peanut allergy treatment AR101, developed by Aimmune Therapeutics Inc. Top-line data from PALISADE, the first phase III study, is expected in the fourth quarter of 2017.